<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89198">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02119052</url>
  </required_header>
  <id_info>
    <org_study_id>ADPKD-liver</org_study_id>
    <nct_id>NCT02119052</nct_id>
  </id_info>
  <brief_title>Effects of Somatostatin on Liver in ADPKD</brief_title>
  <official_title>Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <authority>Italy: Ethics Commettee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autosomal dominant polycystic kidney disease (ADPKD) is associated with the development of a
      variety of extrarenal manifestations of which polycystic liver disease is most common. The
      investigators aimed to assess the changes over time of liver volume in ADPKD patients and
      whether it is affected by the treatment with the somatostatin analogue, octreotide.

      35 ADPKD patients (14 males) aged 34Â±8 years were randomly assigned to 36 month treatment
      with placebo (n=18) or octreotide (n=17). Clinical and liver parameters at magnetic
      resonance (RM) were evaluated at baseline, study end and after 24 months of drug withdrawal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect of somatostatin on liver volume</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>OCTEOTRIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>octeotride 20 mg, intramuscular injection monthly for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline soluction), intramuscular injection monthly for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>octeotride</intervention_name>
    <arm_group_label>OCTEOTRIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of autosomal dominant polycystic kidney and liver disease

          -  glomerular filtration rate greater than 40 ml/min

        Exclusion Criteria:

          -  diabetes mellitus

          -  proteinuria greater than 1 g/24 hours

          -  significant glomerular disease

          -  urinary tract lithiasis and infections

          -  symptomatic gallstones

          -  biliary sludge

          -  cancer

          -  pregnant women

          -  lactanting women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Eleonora Riccio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
